Prenetics Secures $1bn Growth Financing for Beckhams' IM8 Longevity Brand
Prenetics Global has closed a significant US$1 billion growth financing deal with General Catalyst's Customer Value Fund for its IM8 longevity supplement brand, co-founded by David Beckham.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Hong Kong-based Prenetics Global, the parent company behind the IM8 longevity supplement brand, has secured a significant US$1 billion growth financing package from General Catalyst's Customer Value Fund (CVF). This investment directly supports IM8, the supplement range co-founded by David Beckham. Launched in December 2024, IM8 has rapidly established itself in the direct-to-consumer (D2C) supplement market, reporting revenue exceeding US$200 million in less than a year.
The financing agreement includes a critical provision where CVF will cover up to 70% of IM8's marketing expenditures. This structure allows IM8 to maintain complete creative control over its branding and campaigns while substantially de-risking its market expansion strategy. In return for this marketing capital, General Catalyst will receive a capped share of the revenue generated from customer cohorts financed through this deal, linking the investor's return directly to specified new customer acquisition metrics.
This partnership underscores a growing trend of external investment models aimed at accelerating D2C brand growth, particularly in the premium longevity and wellness sectors. For high-profile brands like IM8, backed by celebrity endorsement and NASA-researched formulations, such financing mechanisms can provide a substantial competitive advantage by enabling aggressive marketing spend without immediate equity dilution or drawing heavily on internal cash flows for brand-building activities. The focus on D2C channels highlights efficient customer acquisition strategies and direct engagement, critical for cultivating brand loyalty in a competitive market.
What this means for United Kingdom
UK supplement brand owners should interpret this deal as a benchmark for D2C growth financing structures, particularly those aiming for rapid scaling. The 70% marketing cost coverage model suggests a template for leveraging external capital to intensify market penetration without relinquishing creative autonomy. Brands with strong D2C performance and compelling origin stories may attract similar non-dilutive funding, reducing cash flow strain. This could intensify competition in the UK's premium longevity and wellness categories, potentially driving up customer acquisition costs over the next 12-18 months. Brands must evaluate their own D2C strategies and financial modelling against this new precedent to identify opportunities for similar growth acceleration or prepare for increased market pressure.
The investment will likely bolster IM8's presence and marketing spend, acting as a competitive force in the rapidly expanding longevity market. UK contract manufacturers should anticipate potential requests for increased production capacities from D2C brands seeking aggressive growth, influencing MOQ negotiations and lead times.
Many leading brands in this category are manufactured in partnership with Supplement Factory.